BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011; 17(35): 3971-3975 [PMID: 22046084 DOI: 10.3748/wjg.v17.i35.3971]
URL: https://www.wjgnet.com/1007-9327/full/v17/i35/3971.htm
Number Citing Articles
1
Bruna Maria Roesler, Sandra Cecília Botelho Costa, José Murilo Robilotta Zeitune. Eradication Treatment of Helicobacter pylori Infection: Its Importance and Possible Relationship in Preventing the Development of Gastric CancerISRN Gastroenterology 2012; 2012: 1 doi: 10.5402/2012/935410
2
Seng-Kee Chuah, Wei-Chen Tai, Chen-Hsiang Lee, Chih-Ming Liang, Tsung-Hui Hu. Quinolone-Containing Therapies in the Eradication ofHelicobacter pyloriBioMed Research International 2014; 2014: 1 doi: 10.1155/2014/151543
3
R Ozgur Karaca, Said Kalkisim, Akif Altinbas, Serta Kilincalp, Ilhami Yuksel, Mustafa T Goktas, Umit Yasar, Atilla Bozkurt, Melih O Babaoglu. Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism andHelicobacter pyloriEradicationBasic & Clinical Pharmacology & Toxicology 2017; 120(2): 199 doi: 10.1111/bcpt.12667
4
Natalie Vandeven, Paul Nghiem. Pathogen-Driven Cancers and Emerging Immune Therapeutic StrategiesCancer Immunology Research 2014; 2(1): 9 doi: 10.1158/2326-6066.CIR-13-0179
5
Brygida Kwiatkowska, Maria Maślińska. Macrolide Therapy in Chronic Inflammatory DiseasesMediators of Inflammation 2012; 2012: 1 doi: 10.1155/2012/636157
6
Chuan Wang, Zhifang Jia, Donghui Cao, Lili You, Meishan Jin, Xing Wu, Simin Wen, Xueyuan Cao, Jing Jiang, Valli De Re. Polymorphism of DNA Methyltransferase 3b and Association with Development and Prognosis in Gastric CancerPLOS ONE 2015; 10(8): e0134059 doi: 10.1371/journal.pone.0134059
7
Neus Muñoz, Jordi Sánchez-Delgado, Mireia Baylina, Sheila López-Góngora, Xavier Calvet. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic reviewGastroenterología y Hepatología (English Edition) 2018; 41(10): 654 doi: 10.1016/j.gastre.2018.11.021
8
Wenming Wu, Yunsheng Yang, Gang Sun. Recent Insights into Antibiotic Resistance inHelicobacter pyloriEradicationGastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/723183
9
Hyun Chul Lim, Yong Jae Lee, Byoungrak An, Seung Woo Lee, Yong Chan Lee, Byung Soo Moon. Rifabutin‐based High‐dose Proton‐pump Inhibitor and Amoxicillin Triple Regimen as the Rescue treatment for Helicobacter pylori Helicobacter 2014; 19(6): 455 doi: 10.1111/hel.12147
10
Tzung‐Shiun Wu, Huang‐Ming Hu, Fu‐Chen Kuo, Chao‐Hung Kuo. Eradication of Helicobacter pylori infection The Kaohsiung Journal of Medical Sciences 2014; 30(4): 167 doi: 10.1016/j.kjms.2013.11.003
11
Angelo Zullo, Vincenzo De Francesco, Cesare Hassan, Lorenzo Ridola, Alessandro Repici, Vincenzo Bruzzese, Dino Vaira. Modified sequential therapy regimens for Helicobacter pylori eradication: A systematic reviewDigestive and Liver Disease 2013; 45(1): 18 doi: 10.1016/j.dld.2012.08.025
12
Yanhua Wu, Donghui Cao, Limei Qu, Xueyuan Cao, Zhifang Jia, Tiancheng Zhao, Quan Wang, Jing Jiang. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancerOncotarget 2017; 8(38): 64066 doi: 10.18632/oncotarget.19318
13
Ping-I Hsu, Wen-Chi Chen, Feng-Woei Tsay, Chih-An Shih, Sung-Shuo Kao, Huay-Min Wang, Hsien-Chung Yu, Kwok-Hung Lai, Hui-Hwa Tseng, Nan-Jing Peng, Angela Chen, Chao-Hung Kuo, Deng-Chyang Wu. Ten-Day Quadruple Therapy Comprising Proton-Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin Achieves a High Eradication Rate forHelicobacter pyloriInfection after Failure of Sequential TherapyHelicobacter 2014; 19(1): 74 doi: 10.1111/hel.12085
14
Fariborz Mansour-Ghanaei, Zahra Pedarpour, Afshin Shafaghi, Farahnaz Joukar. Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens for Helicobacter Pylori Infection EradicationMiddle East Journal of Digestive Diseases 2017; 9(2): 100 doi: 10.15171/mejdd.2017.58
15
F. Sierra, J.D. Forero, M. Rey. Ideal treatment for Helicobacter pylori: A systematic reviewRevista de Gastroenterología de México (English Edition) 2014; 79(1): 28 doi: 10.1016/j.rgmxen.2014.05.001
16
Neus Muñoz, Jordi Sánchez-Delgado, Mireia Baylina, Sheila López-Góngora, Xavier Calvet. Prevalencia de las resistencias de Helicobacter pylori tras el fracaso de una primera línea de tratamiento. Revisión sistemáticaGastroenterología y Hepatología 2018; 41(10): 654 doi: 10.1016/j.gastrohep.2018.06.014
17
Ben Wang, You-Hua Wang, Zhi-Fa Lv, Hui-Fang Xiong, Hui Wang, Yang Yang, Yong Xie. Review: Efficacy and Safety of Hybrid Therapy forHelicobacter pyloriInfection: A Systematic Review and Meta-analysisHelicobacter 2015; 20(2): 79 doi: 10.1111/hel.12180
18
Xuan Weng, Suresh Neethirajan, Adam Vogt. Single Cell Chemotactic Responses of Helicobacter pylori to Urea in a Microfluidic ChipApplied Sciences 2016; 6(5): 139 doi: 10.3390/app6050139
19
Jhen-Hong Wong, Kuo-Hao Ho, Sean Nam, Wen-Li Hsu, Chia-Hsien Lin, Che-Mai Chang, Jaw-Yuan Wang, Wei-Chiao Chang. Store-operated Ca2+ Entry Facilitates the Lipopolysaccharide-induced Cyclooxygenase-2 Expression in Gastric Cancer CellsScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-12648-1
20
Seng-Kee Chuah, Wei-Chen Tai, Pin-I Hsu, Deng-Chyang Wu, Keng-Liang Wu, Chung-Mou Kuo, Yi-Chun Chiu, Ming-Luen Hu, Yeh-Pin Chou, Yuan-Hung Kuo, Chih-Ming Liang, King-Wah Chiu, Tsung-Hui Hu. The Efficacy of Second-Line Anti-Helicobacter pyloriTherapy Using an Extended 14-Day Levofloxacin/Amoxicillin/Proton-Pump Inhibitor Treatment - A Pilot StudyHelicobacter 2012; 17(5): 374 doi: 10.1111/j.1523-5378.2012.00960.x
21
Nuno Miguel de Almeida, Alexandra Fernandes, José Manuel Romãozinho, Paulo Freire, Maria M. Donato, Olga Cardoso, Cristina Luxo, Maria Augusta Cipriano, Carol Marinho, Carlos Calhau, Pedro Figueiredo. Correlation of NOD2 genotypes with Helicobacter pylori infection in a South‐European country Advances in Digestive Medicine 2021; 8(3): 163 doi: 10.1002/aid2.13210
22
Natalie Amar, Avi Peretz, Yoram Gerchman. A cheap, simple high throughput method for screening native Helicobacter pylori urease inhibitors using a recombinant Escherichia coli , its validation and demonstration of Pistacia atlantica methanolic extract effectivity and specificityJournal of Microbiological Methods 2017; 133: 40 doi: 10.1016/j.mimet.2016.11.022
23
Mohammad Reza Esmaeili-Dooki, Hossein Shirdel, Mahmood Hajiahmadi. Eradication of Helicobacter pylori in Children by Triple Therapy Regimens of Amoxicillin, Omeprazole, and Clarithromycin or AzithromycinIranian Journal of Pediatrics 2015; 25(6) doi: 10.5812/ijp.2360
24
Hideo Tanaka. Epidemiologic Studies in Cancer Prevention and ScreeningStatistics for Biology and Health 2013; 79: 65 doi: 10.1007/978-1-4614-5586-8_5
25
Halil Rakici, Remzi Adnan Akdoğan, Recep Bedir, Aysegul Copur, Arif Yilmaz. Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy forHelicobacter pyloriinfection: Patients' compliance and bacterial eradication ratesJournal of Digestive Diseases 2014; 15(9): 508 doi: 10.1111/1751-2980.12171
26
JING JIANG, DONG-HUI CAO, TETSUYA TSUKAMOTO, GUO-QING WANG, ZHI-FANG JIA, JIAN SUO, XUE-YUAN CAO. Anticancer effects of 4-vinyl-2,6-dimethoxyphenol (canolol) against SGC-7901 human gastric carcinoma cellsOncology Letters 2013; 5(5): 1562 doi: 10.3892/ol.2013.1230
27
Wei-Chen Tai, Chien-Hua Chiu, Chih-Ming Liang, Kuo-Chin Chang, Chung-Mou Kuo, Yi-Chun Chiu, Keng-Liang Wu, Ming-Luen Hu, Yeh-Pin Chou, Shue-Shian Chiou, King-Wah Chiu, Chung-Huang Kuo, Tsung-Hui Hu, Ming-Tsung Lin, Seng-Kee Chuah. Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in TaiwanGastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/932478
28
Reza Ghotaslou, Morteza Milani, Mohammad Taghi Akhi, Mohammad Saeid Hejazi, Mohammad Reza Nahaei, Alka Hasani, Yaeghob Sharifi. Relationship Between Drug Resistance and cagA Gene in Helicobacter pyloriJundishapur Journal of Microbiology 2013; 6(10) doi: 10.5812/jjm.8480
29
Shu-Ping Xiao, Min Gu, Guo-Xin Zhang. Is levofloxacin-based triple therapy an alternative for first-line eradication ofHelicobacter pylori? A systematic review and meta-analysisScandinavian Journal of Gastroenterology 2014; 49(5): 528 doi: 10.3109/00365521.2014.887765
30
Deng-Chyang Wu, Chao-Hung Kuo, Feng-Woei Tsay, Wen-Hung Hsu, Angela Chen, Ping-I Hsu. A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori InfectionMedicine 2016; 95(11): e2698 doi: 10.1097/MD.0000000000002698
31
Carlo‐Federico Zambon, Daniela Basso, Michela Pelloso, Alberto Tessari, Mario Plebani. Human Emerging and Re‐emerging Infections2015; : 607 doi: 10.1002/9781118644843.ch33
32
Stanisław Ferenc, Jan Gnus, Magdalena Kościelna, Małgorzata Kinda, Andriy Yarka, Luke Stewart, Wojciech Witkiewicz. High antibiotic resistance ofHelicobacter pyloriand its effect on tailored and empiric eradication of the organism in Lower Silesia, PolandHelicobacter 2017; 22(2): e12365 doi: 10.1111/hel.12365
33
Jiunn-Wei Wang, Chien-Ning Hsu, Wei-Chen Tai, Ming-Kun Ku, Tsung-Hsing Hung, Kuo-Lun Tseng, Lan-Ting Yuan, Seng-Howe Nguang, Chih-Ming Liang, Shih-Cheng Yang, Cheng-Kun Wu, Pin-I Hsu, Deng-Chyang Wu, Seng-Kee Chuah, Giuseppe Remuzzi. The Association of Helicobacter pylori Eradication with the Occurrences of Chronic Kidney Diseases in Patients with Peptic Ulcer DiseasesPLOS ONE 2016; 11(10): e0164824 doi: 10.1371/journal.pone.0164824
34
F. Sierra, J.D. Forero, M. Rey. Tratamiento ideal del Helicobacter pylori: una revisión sistemáticaRevista de Gastroenterología de México 2014; 79(1): 28 doi: 10.1016/j.rgmx.2013.03.003
35
Pramodini B. Kale-Pradhan, Anela Mihaescu, Sheila M. Wilhelm. Fluoroquinolone Sequential Therapy for Helicobacter pylori : A Meta-analysisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2015; 35(8): 719 doi: 10.1002/phar.1614
36
Mireia Baylina, Neus Muñoz, Jordi Sánchez‐Delgado, Sheila López‐Góngora, Xavier Calvet, Ignasi Puig. Systematic review: Would susceptibility‐guided treatment achieve acceptable cure rates for second‐line Helicobacter pylori therapy as currently practiced? Helicobacter 2019; 24(3): e12584 doi: 10.1111/hel.12584
37
Neus Muñoz, Jordi Sánchez-Delgado, Mireia Baylina, Ignasi Puig, Sheila López-Góngora, David Suarez, Xavier Calvet. Systematic review, meta-analysis, and meta-regression: Successful second-line treatment for Helicobacter pylori Helicobacter 2018; 23(3): e12488 doi: 10.1111/hel.12488
38
Antonio Rollan, Juan Pablo Arab, M Constanza Camargo, Roberto Candia, Paul Harris, Catterina Ferreccio, Charles S Rabkin, Juan Crist&oacute;bal Gana, Pablo Cort&eacute;s, Rolando Herrero, Luisa Dur&aacute;n, Apolinaria Garc&iacute;a, Claudio Toledo, Alberto Espino, Nicole Lustig, Alberto Sarfatis, Catalina Figueroa, Javier Torres, Arnoldo Riquelme. Management of <italic>Helicobacter pylori</italic> infection in Latin America: A Delphi technique-based consensusWorld Journal of Gastroenterology 2014; 20(31): 10969-10983 doi: 10.3748/wjg.v20.i31.10969
39
Joshua P. Owings, Nina N. McNair, Yiu Fung Mui, Tomas N. Gustafsson, Arne Holmgren, Maria Contel, Joanna B. Goldberg, Jan R. Mead, Lígia Saraiva. Auranofin andN-heterocyclic carbene gold-analogs are potent inhibitors of the bacteriaHelicobacter pyloriFEMS Microbiology Letters 2016; 363(14): fnw148 doi: 10.1093/femsle/fnw148
40
Gaël Tchokomeni Siwe, Rukesh Maharjan, André Perfusion Amang, Christophe Mezui, Nkwengoua Ernestine Zondegoumba, George Enonchong Enow-Orock, Muhammad Iqbal Choudhary, Paul Vernyuy Tan. Eremomastax speciosa (Hochst.) Cufod. counteracts the delaying effect of indomethacin on Helicobacter pylori-associated chronic gastric ulcers healingJournal of Ethnopharmacology 2021; 279: 114374 doi: 10.1016/j.jep.2021.114374
41
Amin Talebi Bezmin Abadi. Helicobacter pylori treatment: New perspectives using current experienceJournal of Global Antimicrobial Resistance 2017; 8: 123 doi: 10.1016/j.jgar.2016.11.008
42
Ping-I Hsu, Pei-Chin Lin, David Y Graham. Hybrid therapy for <italic>Helicobacter pylori</italic> infection: A systemic review and meta-analysisWorld Journal of Gastroenterology 2015; 21(45): 12954-12962 doi: 10.3748/wjg.v21.i45.12954
43
Soohoon Kwon, Dong Ho Lee, Jae Bin Kang, Nayoung Kim, Young Soo Park, Cheol Min Shin, Hyuk Yoon, Yoon Jin Choi. The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure inHelicobacter pyloriEradicationThe Korean Journal of Gastroenterology 2017; 70(2): 72 doi: 10.4166/kjg.2017.70.2.72
44
I. Thung, H. Aramin, V. Vavinskaya, S. Gupta, J. Y. Park, S. E. Crowe, M. A. Valasek. Review article: the global emergence ofHelicobacter pyloriantibiotic resistanceAlimentary Pharmacology & Therapeutics 2016; 43(4): 514 doi: 10.1111/apt.13497
45
Chih-Ming Liang, Chien-Hua Chiu, Hsing-Ming Wang, Wei-Chen Tai, Chih-Chien Yao, Cheng-En Tsai, Chung-Mou Kuo, Yi-Chun Chiu, Keng-Liang Wu, Chen-Hsiang Lee, Kai-Lung Tsai, Chih-Fang Huang, Seng-Kee Chuah. First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in TaiwanBioMed Research International 2017; 2017: 1 doi: 10.1155/2017/3762194
46
F. Sierra, J. D. Forero, M. Rey, M. L. Botero, A. Cárdenas. Pilot study: miscellaneous therapy is highly successful forHelicobacter pylorieradicationAlimentary Pharmacology & Therapeutics 2013; 37(12): 1165 doi: 10.1111/apt.12329
47
Jihee Sung, Nayoung Kim, Yo Han Park, Young Jae Hwang, Soohoon Kwon, Gyeongjae Na, Joon Young Choi, Jae Bin Kang, Hye Rang Kim, Jin-Wook Kim, Dong Ho Lee. Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with forHelicobacter pyloriEradication FailureThe Korean Journal of Gastroenterology 2017; 69(2): 109 doi: 10.4166/kjg.2017.69.2.109
48
E. M. F. Muri, T. G. Barros. Hydroxamic Acids2013; : 241 doi: 10.1007/978-3-642-38111-9_9
49
Hafez Fakheri, Zohreh Bari, Hossein Sardarian. A modified Bismuth-Containing Quadruple Therapy Including a Short Course of Furazolidone for Helicobacter pylori Eradication After Sequential Therapy FailureHelicobacter 2012; 17(4): 264 doi: 10.1111/j.1523-5378.2012.00946.x
50
Sung Woo Jung, Sang Woo Lee. The antibacterial effect of fatty acids on &lt;i&gt;Helicobacter pylori&lt;/i&gt; infectionThe Korean Journal of Internal Medicine 2015; 31(1): 30 doi: 10.3904/kjim.2016.31.1.30
51
S Kane-Dumbre, M. Momin, P. Ravikumar, R. Khatri. DRUG DELIVERY STRATEGIES FOR HELICOBACTER PYLORI INFECTION MANAGEMENT: AN OVERVIEWINDIAN DRUGS 2019; 56(10): 7 doi: 10.53879/id.56.10.11811
52
Seng-Kee Chuah, Ping-I Hsu, Kuo-Chin Chang, Yi-Chun Chiu, Keng-Liang Wu, Yeh-Pin Chou, Ming-Luen Hu, Wei-Chen Tai, King-Wah Chiu, Shue-Shian Chiou, Deng-Chyang Wu, Tsung-Hui Hu. Randomized Comparison of Two Non-Bismuth-Containing Second-line Rescue Therapies for Helicobacter pyloriHelicobacter 2012; 17(3): 216 doi: 10.1111/j.1523-5378.2012.00937.x
53
Mounia Lahbabi, Samia Alaoui, Karima El Rhazi, Mohammed El Abkari, Chakib Nejjari, Afaf Amarti, Bahia Bennani, Mustapha Mahmoud, Adil Ibrahimi, Dafr Allah Benajah. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: Result of the HPFEZ randomised studyClinics and Research in Hepatology and Gastroenterology 2013; 37(4): 416 doi: 10.1016/j.clinre.2012.10.002
54
Chao-Hung Kuo, Fu-Chen Kuo, Huang-Ming Hu, Chung-Jung Liu, Sophie S. W. Wang, Yen-Hsu Chen, Ming-Chia Hsieh, Ming-Feng Hou, Deng-Chyang Wu. The Optimal First-Line Therapy ofHelicobacter pyloriInfection in Year 2012Gastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/168361
55
Jing Yu, Hui Ye, Jiang Li, Ning Li, Zong-ming Shi, Xue-zhi Zhang. The Antibacterial Activity of Mass Galla Chinesis et Camelliae Fermentata on Helicobacter pylori InfectionEvidence-Based Complementary and Alternative Medicine 2018; 2018: 1 doi: 10.1155/2018/1491732
56
Eva M. Kulik Kunz, Krystyna Lenkeit, Tuomas Waltimo, Roland Weiger, Clemens Walter. Combinatorial effects of amoxicillin and metronidazole on selected periodontal bacteria and whole plaque samplesArchives of Oral Biology 2014; 59(6): 608 doi: 10.1016/j.archoralbio.2014.03.007
57
Cheng-En Tsai, Chih-Ming Liang, Chen-Hsiang Lee, Yuan-Hung Kuo, Keng-Liang Wu, Yi-Chun Chiu, Wei-Chen Tai, Seng-Kee Chuah. First-line Helicobacter pylori eradication among patients with chronic liver diseases in TaiwanThe Kaohsiung Journal of Medical Sciences 2016; 32(8): 397 doi: 10.1016/j.kjms.2016.05.012
58
Cuimeng Tian, Keqiang Chen, Wanghua Gong, Teizo Yoshimura, Jiaqiang Huang, Ji Ming Wang. The G-Protein Coupled Formyl Peptide Receptors and Their Role in the Progression of Digestive Tract CancerTechnology in Cancer Research & Treatment 2020; 19: 153303382097328 doi: 10.1177/1533033820973280
59
Ekaterina Gavrish, Binu Shrestha, Chao Chen, Ida Lister, E. Jeffrey North, Lei Yang, Richard E. Lee, Angel Han, Bronwyn Williams, David Charnuska, Ken Coleman, Kim Lewis, Michael D. LaFleur. In Vitro and In Vivo Activities of HPi1, a Selective Antimicrobial against Helicobacter pylori Antimicrobial Agents and Chemotherapy 2014; 58(6): 3255 doi: 10.1128/AAC.02573-13
60
Peng Bai, Li Ya Zhou, Xiu Mei Xiao, Yang Luo, Yu Ding. Susceptibility ofHelicobacter pylorito antibiotics in Chinese patientsJournal of Digestive Diseases 2015; 16(8): 464 doi: 10.1111/1751-2980.12271
61
A. O. Pozdeeva, O. K. Pozdeev, P. E. Gulyaev, Yu. V. Valeeva, A. N. Savinova. Current development of <i>Helicobacter pylori</i> eradication protocolsRussian Journal of Infection and Immunity 2021; 11(6): 1037 doi: 10.15789/2220-7619-CDO-1679
62
Hyung Min Noh, Su Jin Hong, Jae Pil Han, Kyung Woo Park, Yun Nah Lee, Tae Hee Lee, Bong Min Ko, Joon Seong Lee, Moon Sung Lee. Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin afterHelicobacter pyloriTreatment Failure in Clinical PracticeThe Korean Journal of Gastroenterology 2016; 68(5): 260 doi: 10.4166/kjg.2016.68.5.260
63
Soohoon Kwon, Dong Ho Lee, Jae Bin Kang, Nayoung Kim, Young Soo Park, Cheol Min Shin, Hyuk Yoon, Yoon Jin Choi. The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure inHelicobacter pyloriEradicationThe Korean Journal of Gastroenterology 2018; 71(4): 196 doi: 10.4166/kjg.2018.71.4.196
64
Sukhbir K Shahid. Novel anti-Helicobacter pylori therapiesPharmaceutical Patent Analyst 2014; 3(4): 411 doi: 10.4155/ppa.14.27
65
Jun-Won Chung, Young Kul Jung, Yoon Jae Kim, Kwang Ahn Kwon, Jung Ho Kim, Jong Joon Lee, Sung Min Lee, Ki Baik Hahm, Sun Mi Lee, Jin Yong Jeong, Sung-Cheol Yun. Ten-day sequentialversustriple therapy forHelicobacter pylorieradication: A prospective, open-label, randomized trialJournal of Gastroenterology and Hepatology 2012; 27(11): 1675 doi: 10.1111/j.1440-1746.2012.07249.x
66
Li-Yuan Yu, Lu-Ning Sun, Xue-Hui Zhang, Yue-Qi Li, Lei Yu, Zi-Qing-Yun Yuan, Ling Meng, Hong-Wen Zhang, Yong-Qing Wang. A Review of the Novel Application and Potential Adverse Effects of Proton Pump InhibitorsAdvances in Therapy 2017; 34(5): 1070 doi: 10.1007/s12325-017-0532-9
67
Acacia Lamb, Lin-Feng Chen. Role of theHelicobacter pylori-Induced inflammatory response in the development of gastric cancerJournal of Cellular Biochemistry 2013; 114(3): 491 doi: 10.1002/jcb.24389
68
Yingling Jiang, Lifang Huang, Lihua Zhou. Association between obesity and helicobacter pylori infectionNutrition Clinique et Métabolisme 2022; 36(3): 210 doi: 10.1016/j.nupar.2022.07.003
69
Feng-Woei Tsay, Deng-Chyang Wu, Sung-Shuo Kao, Tzung-Jium Tsai, Kwok-Hung Lai, Jin-Shiung Cheng, Hoi-Hung Chan, Huay-Min Wang, Wei-Lun Tsai, Hui-Hwa Tseng, Nan-Jin Peng, Ping-I Hsu. Reverse Sequential Therapy Achieves a Similar Eradication Rate as Standard Sequential Therapy forHelicobacter pyloriEradication: A Randomized Controlled TrialHelicobacter 2015; 20(1): 71 doi: 10.1111/hel.12176
70
Katayoun Borhani, Ashraf Mohabati Mobarez, Ali Reza Khabiri, Mehrdad Behmanesh, Nima Khoramabadi. Inhibitory effects of rHP-NAP IgY against Helicobacter pylori attachment to AGS cell lineMicrobial Pathogenesis 2016; 97: 231 doi: 10.1016/j.micpath.2016.06.004
71
Maria Harmati, Edina Gyukity-Sebestyen, Gabriella Dobra, Gabriella Terhes, Edit Urban, Gabor Decsi, Neda Mimica-Dukić, Marija Lesjak, Nataša Simin, Bernadett Pap, Istvan B. Nemeth, Krisztina Buzas. Binary mixture ofSatureja hortensisandOriganum vulgaresubsp.hirtumessential oils: in vivo therapeutic efficiency againstHelicobacter pyloriinfectionHelicobacter 2017; 22(2): e12350 doi: 10.1111/hel.12350
72
Jayaram Lakshmaiah Narayana, Han-Ning Huang, Chang-Jer Wu, Jyh-Yih Chen. Epinecidin-1 antimicrobial activity: In vitro membrane lysis and In vivo efficacy against Helicobacter pylori infection in a mouse modelBiomaterials 2015; 61: 41 doi: 10.1016/j.biomaterials.2015.05.014
73
Seng-Kee Chuah, Deng-Chyang Wu, Hidekazu Suzuki, Khean-Lee Goh, John Kao, Jian-Lin Ren. Peptic Ulcer Diseases: Genetics, Mechanism, and TherapiesBioMed Research International 2014; 2014: 1 doi: 10.1155/2014/898349
74
P. Nazari, R. Dowlatabadi-Bazaz, M. R. Mofid, M. R. Pourmand, N. E. Daryani, M. A. Faramarzi, Z. Sepehrizadeh, A. R. Shahverdi. The Antimicrobial Effects and Metabolomic Footprinting of Carboxyl-Capped Bismuth Nanoparticles Against Helicobacter pyloriApplied Biochemistry and Biotechnology 2014; 172(2): 570 doi: 10.1007/s12010-013-0571-x
75
Te-Fu Lin, Ping-I Hsu. Second-line rescue treatment of <i>Helicobacter pylori</i> infection: Where are we now?World Journal of Gastroenterology 2018; 24(40): 4548-4553 doi: 10.3748/wjg.v24.i40.4548
76
Nuno Almeida, Maria Manuel Donato, José Manuel Romãozinho, Cristina Luxo, Olga Cardoso, Maria Augusta Cipriano, Carol Marinho, Alexandra Fernandes, Carlos Sofia. Correlation of Helicobacter pylori Genotypes with Gastric Histopathology in the Central Region of a South-European CountryDigestive Diseases and Sciences 2015; 60(1): 74 doi: 10.1007/s10620-014-3319-8
77
Shen-Shong Chang, Hsiao-Yun Hu. <italic>Helicobacter pylori</italic>: Effect of coexisting diseases and update on treatment regimensWorld Journal of Gastrointestinal Pharmacology and Therapeutics 2015; 6(4): 127-136 doi: 10.4292/wjgpt.v6.i4.127
78
Lucinda J. Bessa, Rossella Grande, Donato DI Iorio, Mara DI Giulio, Emanuela DI Campli, Luigina Cellini. Helicobacter pylorifree-living and biofilm modes of growth: behavior in response to different culture mediaAPMIS 2013; 121(6): 549 doi: 10.1111/apm.12020
79
Bekir Kocazeybek, Hrisi Bahar Tokman. Prevalence of Primary Antimicrobial Resistance ofH. pyloriin Turkey: A Systematic ReviewHelicobacter 2016; 21(4): 251 doi: 10.1111/hel.12272
80
Hang Yeon Jeong, Tae Ho Lee, Ju Gyeong Kim, Sueun Lee, Changjong Moon, Xuan Trong Truong, Tae-Il Jeon, Jae-Hak Moon. 3-Pentylcatechol, a Non-Allergenic Urushiol Derivative, Displays Anti-Helicobacter pylori Activity In VivoPharmaceuticals 2020; 13(11): 384 doi: 10.3390/ph13110384
81
Nuno Almeida, José M. Romãozinho, Maria M. Donato, Cristina Luxo, Olga Cardoso, Maria A. Cipriano, Carol Marinho, Carlos Sofia. Triple Therapy with High-Dose Proton-Pump Inhibitor, Amoxicillin, and Doxycycline Is Useless forHelicobacter pyloriEradication: A Proof-of-Concept StudyHelicobacter 2014; 19(2): 90 doi: 10.1111/hel.12106
82
Ping-I Hsu, Nan-Jing Peng. H. pyloriEradication TherapyGastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/935635
83
Xue-Yuan Cao, Zhi-Fang Jia, Dong-Hui Cao, Fei Kong, Mei-Shan Jin, Jian Suo, Jing Jiang. DNMT3a rs1550117 Polymorphism Association with Increased Risk of Helicobacter pylori InfectionAsian Pacific Journal of Cancer Prevention 2013; 14(10): 5713 doi: 10.7314/APJCP.2013.14.10.5713
84
M. Gasparetto, M. Pescarin, G. Guariso. Helicobacter pyloriEradication Therapy: Current AvailabilitiesISRN Gastroenterology 2012; 2012: 1 doi: 10.5402/2012/186734
85
Angelo Zullo, Cesare Hassan, Lorenzo Ridola, Vincenzo De Francesco, Dino Vaira. Standard triple and sequential therapies for Helicobacter pylori eradication: An updateEuropean Journal of Internal Medicine 2013; 24(1): 16 doi: 10.1016/j.ejim.2012.07.006
86
Jun-Won Chung, Minsu Ha, Sung-Cheol Yun, Jung Ho Kim, Jong Jun Lee, Yoon Jae Kim, Kyoung Oh Kim, Kwang An Kwon, Dong Kyun Park, Dong Ho Lee. Meta-analysis: Sequential Therapy Is Superior to Conventional Therapy forHelicobacter pyloriInfection in KoreaThe Korean Journal of Gastroenterology 2013; 62(5): 267 doi: 10.4166/kjg.2013.62.5.267
87
Hyasinta Jaka, Andreas Mueller, Christa Kasang, Stephen E. Mshana. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective studyBMC Infectious Diseases 2019; 19(1) doi: 10.1186/s12879-019-4085-1
88
Olga Cardoso, Maria Manuel Donato, Cristina Luxo, Nuno Almeida, Joana Liberal, Artur Figueirinha, Maria Teresa Batista. Anti- Helicobacter pylori potential of Agrimonia eupatoria L. and Fragaria vescaJournal of Functional Foods 2018; 44: 299 doi: 10.1016/j.jff.2018.03.027
89
Morris O. Makobongo, Leo Einck, Richard M. Peek, D. Scott Merrell, Asad U Khan. In Vitro Characterization of the Anti-Bacterial Activity of SQ109 against Helicobacter pyloriPLoS ONE 2013; 8(7): e68917 doi: 10.1371/journal.pone.0068917
90
Amin Talebi Bezmin Abadi. Therapy ofHelicobacter pylori: Present Medley and Future ProspectiveBioMed Research International 2014; 2014: 1 doi: 10.1155/2014/124607
91
Wei-Chen Tai, Chen-Hsiang Lee, Shue-Shian Chiou, Chung-Mou Kuo, Chung-Huang Kuo, Chih-Ming Liang, Lung-Sheng Lu, Chien-Hua Chiu, Keng-Liang Wu, Yi-Chun Chiu, Tsung-Hui Hu, Seng-Kee Chuah, Ivo G. Boneca. The Clinical and Bacteriological Factors for Optimal Levofloxacin-Containing Triple Therapy in Second-Line Helicobacter pylori EradicationPLoS ONE 2014; 9(8): e105822 doi: 10.1371/journal.pone.0105822
92
Halil Rakici, Teslime Ayaz, Remzi Adnan Akdogan, Recep Bedir. Comparison of Levofloxacin- and Moxifloxacin-Based Triple Therapies with Standard Treatment in Eradication of Helicobacter Pylori as First-Line TherapyDigestion 2014; 90(4): 261 doi: 10.1159/000369788
93
Seng-Kee Chuah, Chih-Ming Liang, Chen-Hsiang Lee, Shue-Shian Chiou, Yi-Chun Chiu, Ming-Luen Hu, Keng-Liang Wu, Lung-Sheng Lu, Yeh-Pin Chou, Kuo-Chin Chang, Chung-Huang Kuo, Chung-Mou Kuo, Tsung-Hui Hu, Wei-Chen Tai. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori EradicationMedicine 2016; 95(19): e3586 doi: 10.1097/MD.0000000000003586
94
Ping-I Hsu, Sung-Shuo Kao, Deng-Chyang Wu, Wen-Chi Chen, Nan-Jing Peng, Hsien-Chung Yu, Huay-Min Wang, Kwok-Hung Lai, Jin-Shiung Cheng, Angela Chen, Seng-Kee Chuah, Feng-Woei Tsay. A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori InfectionMedicine 2015; 94(48): e2104 doi: 10.1097/MD.0000000000002104
95
Thomas A Keating. Resistance mechanism to an uncompetitive inhibitor of a single-substrate, single-product enzyme: a study of Helicobacter pylori glutamate racemaseFuture Medicinal Chemistry 2013; 5(11): 1203 doi: 10.4155/fmc.13.94
96
Sotirios D. Georgopoulos, Vasilios Papastergiou, Stylianos Karatapanis. Helicobacter  pyloriEradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved EfficacyGastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/757926
97
Maliheh Safavi, Mohammadreza Shams-Ardakani, Alireza Foroumadi. Medicinal plants in the treatment ofHelicobacter pyloriinfectionsPharmaceutical Biology 2015; 53(7): 939 doi: 10.3109/13880209.2014.952837
98
Nuno Almeida, Maria Manuel Donato, José Manuel Romãozinho, Cristina Luxo, Olga Cardoso, Maria Augusta Cipriano, Carol Marinho, Alexandra Fernandes, Carlos Calhau, Carlos Sofia. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country?BMC Gastroenterology 2015; 15(1) doi: 10.1186/s12876-015-0245-y
99
Yi-Chun Chiu, Wei-Chen Tai, Seng-Kee Chuah, Ping-I Hsu, Deng-Chyang Wu, Keng-Liang Wu, Chao-Cheng Huang, Ji-Chen Ho, Johannes Ring, Wen-Chieh Chen. The Clinical Correlations ofHelicobacter pyloriVirulence Factors and Chronic Spontaneous UrticariaGastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/436727